Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Response to first-line treatment and histology are associated with achieving complete remission after the first salvage high-dose chemotherapy in relapsing germ cell tumor patients

Bone Marrow Transplantation volume 53, pages 820–825 (2018)Cite this article

Subjects

Abstract

Sequential high-dose chemotherapy (HDCT) with autologous stem cell transplantation (ASCT) is a curative option in relapsing germ cell tumor (GCT) patients, and complete remission (CR) after the first ASCT (early CR2) is associated with favorable outcome. Prognostic factors predicting early CR2 have not been investigated so far. We analyzed consecutive patients with a first relapse of GCT treated with three sequential cycles of carboplatin/etoposide-based HDCT with ASCT in the two largest academic centers in Switzerland. The cohort comprised 96 relapsing GCT patients, with 19 (19.8%) patients achieving early CR2 after the first HDCT cycle. The median progression-free survival and overall survival were not reached in patients achieving early CR2, whereas they were 9.6 months (P = 0.0301) and 34.8 months (P = 0.0684) for patients missing early CR2. Patients with early CR2 more often had CR1 after first-line bleomycin, etoposide, and cisplatin chemotherapy (68.4 vs. 31.6%; P = 0.0037) and an interval longer than 2 years between initial diagnosis and first HDCT (36.8 vs. 15.6%; P = 0.0373), but less often a histology of mixed nonseminomatous tumor (46.8 vs. 21.1%; P = 0.0418). These data suggest that response to first-line chemotherapy, late relapse, and histology are associated with achieving early CR2 after a first HDCT with ASCT in relapsing GCT patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1

Similar content being viewed by others

References

  1. Beyer J, Kingreen D, Krause M, Schleicher J, Schwaner I, Schwella N, et al. Long term survival of patients with recurrent or refractory germ cell tumors after high dose chemotherapy. Cancer. 1997;79:161–8.

    Article  PubMed  CAS  Google Scholar 

  2. Einhorn LH, Williams SD, Chamness A, Brames MJ, Perkins SM, Abonour R. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med. 2007;357:340–8.

    Article  PubMed  CAS  Google Scholar 

  3. Lorch A, Bascoul-Mollevi C, Kramar A, Einhorn L, Necchi A, Massard C, et al. Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: Evidence from a large international database. J Clin Oncol. 2011;29:2178–84.

    Article  PubMed  Google Scholar 

  4. Nichols CR, Tricot G, Williams SD, van Besien K, Loehrer PJ, Roth BJ, et al. Dose-intensive chemotherapy in refractory germ cell cancer—a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol. 1989;7:932–9.

    Article  PubMed  CAS  Google Scholar 

  5. Nichols CR, Andersen J, Lazarus HM, Fisher H, Greer J, Stadtmauer EA, et al. High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer: an Eastern Cooperative Oncology Group protocol. J Clin Oncol. 1992;10:558–63.

    Article  PubMed  CAS  Google Scholar 

  6. Broun ER, Nichols CR, Turns M, Williams SD, Loehrer PJ, Roth BJ, et al. Early salvage therapy for germ cell cancer using high dose chemotherapy with autologous bone marrow support. Cancer. 1994;73:1716–20.

    Article  PubMed  CAS  Google Scholar 

  7. Siegert W, Beyer J, Strohscheer I, Baurmann H, Oettle H, Zingsem J, et al. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study—The German Testicular Cancer Cooperative Study Group. J Clin Oncol. 1994;12:1223–31.

    Article  PubMed  CAS  Google Scholar 

  8. Motzer RJ, Mazumdar M, Bosl GJ, Bajorin DF, Amsterdam A, Vlamis V. High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: treatment results and prognostic factors for survival and toxicity. J Clin Oncol. 1996;14:1098–105.

    Article  PubMed  CAS  Google Scholar 

  9. Motzer RJ, Mazumdar M, Sheinfeld J, Bajorin DF, Macapinlac HA, Bains M, et al. Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients. J Clin Oncol. 2000;18:1173–80.

    Article  PubMed  CAS  Google Scholar 

  10. Lorch A, Kleinhans A, Kramar A, Kollmannsberger CK, Hartmann JT, Bokemeyer C, et al. Sequential versus single high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: long-term results of a prospective randomized trial. J Clin Oncol. 2012;30:800–5.

    Article  PubMed  CAS  Google Scholar 

  11. Lorch A, Kollmannsberger C, Hartmann JT, Metzner B, Schmidt-Wolf IG, Berdel WE. et al. German Testicular Cancer Study Group. Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group. J Clin Oncol. 2007;25:2778–84.

    Article  PubMed  CAS  Google Scholar 

  12. Gerl A, Clemm C, Schmeller N, Hartenstein R, Lamerz R, Wilmanns W. Prognosis after salvage treatment for unselected male patients with germ cell tumours. Br J Cancer. 1995;72:1026–32.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  13. Beyer J, Kramar A, Mandanas R, Linkesch W, Greinix A, Droz JP, et al. High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables. J Clin Oncol. 1996;14:2638–45.

    Article  PubMed  CAS  Google Scholar 

  14. Fossa SD, Stenning SP, Gerl A, Horwich A, Clark PI, Wilkinson PM, et al. Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours. Br J Cancer. 1999;80:1392–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  15. Motzer RJ, Nichols CJ, Margolin KA, Bacik J, Richardson PG, Vogelzang NJ, et al. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol. 2007;25:247–56.

    Article  PubMed  CAS  Google Scholar 

  16. Sammler C, Beyer J, Bokemeyer C, Hartmann JT, Rick O. Risk factors in germ cell tumour patients with relapse or progressive disease after first-line chemotherapy: evaluation of a prognostic score for survival after high-dose chemotherapy. Eur J Cancer. 2008;44:237–43.

    Article  PubMed  CAS  Google Scholar 

  17. Lorch A, Beyer J, Bascoul-Mollevi C, Kramar A, Einhorn LH, Necchi A, et al. Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. J Clin Oncol. 2010;28:4906–11.

    Article  PubMed  CAS  Google Scholar 

  18. Gössi F, Spahn M, Zweifel M, Samaras P, Mischo A, Stenner F, et al. Comparison of three or fewer high-dose chemotherapy cycles as salvage treatment in germ cell tumors in first relapse. Bone Marrow Transplant. 2016;52:334–6.

    Article  PubMed  CAS  Google Scholar 

  19. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–81.

    Article  Google Scholar 

  20. Fankhauser CD, Curioni-Fontecedro A, Allmann V, Beyer J, Tischler V, Sulser T, et al. Frequent PD-L1 expression in testicular germ cell tumors. Br J Cancer. 2015;113:411–3.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Acknowledgements

We thank the data management team of the university hospitals in Bern and Zurich for providing data used in this study. This work was supported by grants from the Swiss Cancer League (#38–167).

Author contributions

FG performed research and analyzed data; MS contributed vital material; PS contributed vital material; JB contributed vital material; JS contributed vital material; and TP designed research and analyzed data. All authors participated in drafting or reviewing the report, and all authors approved the submitted version.

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland

    Flavio Gössi, Julian Schardt & Thomas Pabst

  2. Department of Urology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland

    Martin Spahn

  3. Department of Oncology, University Hospital Zurich, Zurich, Switzerland

    Panagiotis Samaras & Jörg Beyer

Authors
  1. Flavio Gössi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Martin Spahn
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Panagiotis Samaras
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jörg Beyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Julian Schardt
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Thomas Pabst
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas Pabst.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gössi, F., Spahn, M., Samaras, P. et al. Response to first-line treatment and histology are associated with achieving complete remission after the first salvage high-dose chemotherapy in relapsing germ cell tumor patients. Bone Marrow Transplant 53, 820–825 (2018). https://doi.org/10.1038/s41409-018-0089-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-018-0089-5

Search

Advanced search

Quick links